We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current AGYTF market cap is 247.85M. The company's latest EPS is GBP -0.0084 and P/E is -7.32.
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 78.2M | 84.33M | 72.77M | 59.59M | 55.2M |
| Operating Income | 10.06M | 2.03M | -14.21M | -38.77M | -35.26M |
| Net Income | 7.06M | 2.89M | -13.78M | -43.07M | -40.22M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 86.23M | 88.09M | 72.95M | 66.77M | 64.83M |
| Total Liabilities | 42.44M | 39.55M | 35.18M | 64.7M | 61.12M |
| Total Equity | 43.78M | 48.54M | 37.77M | 2.07M | 3.71M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | 12.01M | 8.4M | -14M | -28.88M | -32.14M |
| Investing | -2.51M | -2.64M | -3M | -4.59M | -1.2M |
| Financing | -110k | -2.03M | -2.81M | 27.8M | 31.43M |
| Market Cap | 247.85M |
| Price to Earnings Ratio | -7.32 |
| Price to Sales Ratio | 5.3 |
| Price to Cash Ratio | 22.78 |
| Price to Book Ratio | 79.03 |
| Dividend Yield | - |
| Shares Outstanding | 4.77B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 160.00% |
| 52 Week High | 0.06 |
| 52 Week Low | 0.02 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Allergy Therapeutics Plc (PK) |
| Address |
dominion way west sussex BN14 8SA |
| Website | https://www.allergytherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
